2.0 LPBI Executive Summary

2.0 LPBI Group, 2021 – 2025

Executive Summary

Prepared by

Aviva Lev-Ari, PhD, RN

and

2.0 LPBI Board Members

Stephen J. Williams, PhD, Marcus W. Feldman, PhD and Joel Shertok, PhD

The Voice of Aviva Lev-Ari, 2.0 LPBI, Founder

Updated on 2/1/2021

Milestone achieved today:

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Thought on the transition

One Possible Strategy for an Acquisition is via a SPAC

https://pharmaceuticalintelligence.com/2021/01/30/one-possible-strategy-for-an-acquisition-is-via-a-spac/

We are offering a unique opportunity to acquire the intellectual and physical assets of Leaders in Pharmaceutical Business Intelligence (LPBI), a scholarly enterprise that has pioneered the scientific curation of medical/pharmaceutical research. We anticipate revenues of $100MM over the next five years [Valuation of 2012-2020 Portfolio of IP and six pipelines to be pursued in 2021-2025.]

We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies:

https://pharmaceuticalintelligence.com/vision/

Our a portfolio of Intellectual Property Assets reaches 2MM e-Readers while offering 6,000 superior interpretive articles within five specialties of Medicine and Life Sciences.

We have created 16 books which have been downloaded ~125,000 times. LPBI researchers have covered in real time (both in writing and via Tweets) 100 of the top biotech and medical conferences over 8 years. All of LPBI’s content was created by our Experts, Authors, and Writers (EAWs).

LPBI is developing new strategies in AI and Blockchain technologies for application within LPBI’s content, for INSIGHT and pattern recognition by automated Machine Learning algorithms, to enhance drug discovery and drug repurposing,

LPBI’s vision for the coming five years includes:

Content conversion by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds. Classification and clustering of concepts, context, processes and pathways.
Conversion of our written content to Audio. We will convert English text to such foreign languages as Japanese, Spanish and Russian.

Three transformational transitions:

From our current Open Access system, we will transition to Blockchain-based transaction networks.
From Digital Cloud-based articles, we will create audio and video Podcasts
From a sole owner-operator status, we will transition to Joint Ventures, M&A, and Partnerships

There are two strategic dimensions related this transformation:

Our deep expertise and innovations in media platforms and content creation will have a new focus: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia
Our created content will become the basis of our content mining, and the subject of managed computerized text analysis under supervised learning guided by our own team of experts

Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences

Strength of 2.0 LPBI

1. Strong scientific curation makes basic research readily available to wide range of scholars, practitioners and students in biomedical science

2. The books are convenient and comprehensive compendia of the latest scholarship.

3. The updating methodology keeps material current

4. Reporting on conferences and meetings gives the audience early access to the latest technologies in biomedicine

5. Curation methodology is transferable across disciplines and languages allowing for big international and interdisciplinary markets

6. The pricing analysis has been carefully researched across multimedia platforms

Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology

Our Ideas are Products of our Environment

The complex and rapid deluge of scientific information, absence of a collaborative, open environment to produce transformative innovation, and dearth of alternative ways to disseminate scientific findings has led to major operational inefficiencies in the biomedical and pharma industries, to the tune of millions of dollars per year. These issues have driven the need for a more context-driven architecture for knowledge and discourse within the biomedical arena. The process of curation decreases time for assessment of current trends adding multiple insights, analyses WITH an underlying METHODOLOGY, provides insights from WHOLE scientific community on multiple WEB 2.0 platforms, and makes use of new computational and Web-based tools to provide interoperability of data, reporting of findings.

At Leaders in Pharmaceutical Business Intelligence (LPBI) Group venture owner and Editor-in-Chief, Aviva Lev-Ari, PhD, RN has been developing a strategy for the

facilitation of Global access to Biomedical knowledge rather than the access to sheer search results on Scientific subject matters in the Life Sciences and Medicine”. According to Aviva, “for the methodology to attain this complex goal it is to be dealing with popularization of ORIGINAL Scientific Research via Content Curation of Scientific Research Results by Experts, Authors, Writers using the critical thinking process of expert interpretation of the original research results.

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields. This curative process establishes new connections and produces new and transformative ideas.

Using our curation methodology, LPBI has produced an open-access online scientific journal, a series of 16 BioMed e-books, and Real-time press coverage of scientific conferences, all of which are optimally designed for novel Text Analysis methods using leading AI, ML and NLP algorithms from 3rd parties software applied on LPBI’s own content customizing the applications for the needs developed by LPBI in the classification and clustering of the Semantics in our contents: Journal articles (6,000) e-Books (16) Conferences content (100).

Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

From our Past to our Future

Currently, there is a digital information explosion in both the Life Sciences and Medical arenas. Tracking new information and discoveries, while guarding against obsolescence, is a major issue for scientists working in these fields.

To overcome these challenges, the Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

LPBI (previously an equity sharing, non-profit entity) is now making its intellectual and digital intellectual properties available for sale to outside entities that are willing to take over and extend our reach.

Through use of AI, NLP, Audio Podcasts and additional advanced Machine Learning technologies, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content [not including the valuation of 2012-2020 portfolio of IP.]

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields.

This enables the LPBI Group to respond to the needs of our scientific audiences, guarding against information obsolescence and overload, through innovative digital technologies and solutions, via:

An open-access online scientific journal
A series of 16 BioMed e-books.
Real-time press coverage with real-time Twitter posting of speakers quotes during conferences.

These have been made widely available to the scientific and non-research community by the Open Access feature of LPBI’s Journal’s website PharmaceuticalIntelligence.com.

November 2020

2.0 LPBI Group’s Team

We describe below our vision for the evolution over the next five years of the existing pharmaceutical media venture, aka, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston. Our team members are in MA, NJ, India, CA, PA, Canada, ME and DE. Our web site is http://pharmaceuticalintelligence.com.

On January 2021, LPBI Group will transition from 1.0 LPBI to 2.0 LPBI. The description of 2.0 LPBI is included in the following three sources:

https://pharmaceuticalintelligence.com/vision/
https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/
Three Sheets in an Excel file named MASTER_FINANCIALS-1.0-2.0-COMBINED.xlsx

2.0 LPBI Excel Spreadsheet – the financial prospects for LPBI for the future five years, as they represent new strategies for the existing ten IP Asset Classes developed since 2012 by the Founder and the Team of 1.0 LPBI.

Sheet #2

1.0 LPBI Group’s List of 10 IP Asset Classes described with Financial Revenue Potential in

Sheet #1

Combined 1.0 LPBI [(2012-2020) + (2021-2025)] and 2.0 LPBI [2021 – 2025] are exhibited in

Sheet #3

2.0 LPBI has developed transformational strategies for the natural progression from 1.0 LPBI Group’s List of 10 IP Asset Classes. These strategies are described below in detail.